Big Pharma’s Response to Trump’s Commercial Drug Pricing
- Uncertainty surrounding potential tariffs on pharmaceutical products, a lingering policy from the Trump governance, continues to ripple through the pharmaceutical industry.
- Some companies are considering shifting investments overseas, while others are adopting a wait-and-see approach.
- AbbVie,an Illinois-based pharmaceutical company,recently raised its profit forecasts for 2025,citing strong sales of new autoimmune treatments.
Trump-Era Tariff Threats Loom Over Big Pharma, Sparking Uncertainty
Table of Contents
- Trump-Era Tariff Threats Loom Over Big Pharma, Sparking Uncertainty
- Big Pharma Under Tariff Threat: A Q&A Guide
- Frequently Asked Questions
- Q: What is the main concern regarding tariffs in the pharmaceutical industry?
- Q: How could tariffs affect the financial performance of pharmaceutical companies?
- Q: Are there any companies that are already feeling the effects of current tariffs?
- Q: What steps are pharmaceutical companies considering in response to potential tariffs?
- Q: How could tariffs impact drug costs in the United states?
- Q: Which countries are the major exporters of pharmaceuticals to the U.S.?
- Q: How are analysts advising investors considering these tariff threats?
- Q: Which pharmaceutical companies do analysts recommend as potential investments?
- Q: What are the challenges facing the pharmaceutical sector aside from tariff threats?
- Q: How are leading companies like Eli Lilly positioned in the market?
- Frequently Asked Questions
Uncertainty surrounding potential tariffs on pharmaceutical products, a lingering policy from the Trump governance, continues to ripple through the pharmaceutical industry. While the tariffs are not yet in effect, their potential impact is already causing concern among major players.
Some companies are considering shifting investments overseas, while others are adopting a wait-and-see approach. Analysts are closely monitoring the situation, offering their perspectives on how these tariffs coudl affect the sector.
AbbVie,an Illinois-based pharmaceutical company,recently raised its profit forecasts for 2025,citing strong sales of new autoimmune treatments. However,the company cautioned that these forecasts do not factor in potential changes in trade policy.
In a press release, abbvie stated that its updated profit guidance, projecting earnings between $12.09 and $12.29 per share, ”does not reflect any changes in commercial policy, including pharmaceutical sector rates, which could impact business activity.”
Weighing the Costs: AbbVie, Merck, and Johnson & Johnson
AbbVie anticipates a $30 million impact from existing tariffs, primarily related to its aesthetics business, according to
Bloomberg
. Managing Director Rob Michael suggested this impact would be comparable to that experienced by competitors. AbbVie also plans to invest $10 billion in the U.S. over the next decade.
In contrast,larger pharmaceutical companies like Johnson & Johnson and Merck have issued more stark warnings about the potential financial burden of tariffs. Merck,headquartered in New Jersey,estimates that current tariffs,including a 10% levy on worldwide imports,will cost the company $200 million this year,
The Guardian
reported. This figure also accounts for retaliatory tariffs imposed by foreign governments, especially China.
These estimates, tho, do not include the potential impact of more significant tariffs specifically targeting pharmaceutical imports.
Despite the tariff threats,
Barron’s
reports that most analysts do not anticipate tariffs on pharmaceutical products reaching triple-digit levels. however, they are advising investors to favor companies with less exposure to the potential negative impacts of these trade policies and other challenges facing the industry.
Cantor Fitzgerald analysts, in a note published last week, stated a preference for “dominant companies with rapid revenue growth and strong sales and profit prospects through the 2030s, as well as relatively less exposure to potential duties.”
Specifically, cantor Fitzgerald favors Eli lilly, AbbVie, and Regeneron Pharmaceuticals, assigning them an “Overweight” rating. Gilead Sciences, vertex Pharmaceuticals, and Vaxcyte, all U.S.-based companies, also received this rating.
Eli Lilly’s Anti-Obesity Drug Pipeline
Cantor Fitzgerald analyst Carter Gould anticipates that Eli Lilly, a major drug manufacturer, will further solidify its position in the anti-obesity drug market. Eli Lilly,the maker of Zepbound and Mounjaro,saw its stock rise following promising clinical trial results for its new weight-loss pill,Orforglipron.
This could give Eli Lilly an advantage over Novo Nordisk, the Danish company that produces Ozempic and Wegovy, currently the only other drugs approved by the Food and Drug Administration for weight loss.
Focus on Domestic Production
following the success of COVID-19 vaccines, the pharmaceutical sector has faced challenges including slow growth, missed forecasts, and clinical trial setbacks.According to
Barron’s
, the threat of tariffs has contributed to a decline in pharmaceutical company shares, down 4% this year and 7% since the start of 2024.
Jefferies analyst Akash Tewari estimates that a 25% tariff could reduce sector profits by approximately 15%. However,Tewari suggests that “mitigation efforts,such as stockpiling,increasing drug prices,or shifting production to the United States,could reduce the damage to a low single-digit figure.” Tewari believes companies with significant U.S.-based sales, production, and intellectual property are the safest investments.
Potential Impact on U.S.Drug Costs
While the Trump administration’s policies aim to incentivize domestic production, a report by Ernst & Young, as cited by
Reuters
, suggests that a 25% tariff on pharmaceutical imports could increase U.S. drug costs by nearly $51 billion annually, possibly raising prices by up to 12.9%.
The report also found that in 2023,the U.S. imported $203 billion worth of pharmaceutical products, with 73% originating from Europe, particularly Ireland, Germany, and Switzerland. Total pharmaceutical sales in the U.S. that year amounted to $393 billion.
Big Pharma Under Tariff Threat: A Q&A Guide
The pharmaceutical industry is navigating a complex landscape of challenges,from post-pandemic market shifts to potential trade policy changes. One meaningful concern for major players revolves around the lingering possibility of tariffs on pharmaceutical products, a policy with roots in the Trump administration. This guide answers key questions about the potential impact of these tariffs and their implications for investors and consumers.
Frequently Asked Questions
Q: What is the main concern regarding tariffs in the pharmaceutical industry?
A: The primary concern revolves around the potential implementation of tariffs on pharmaceutical imports. While these tariffs aren’t currently in effect, their possible imposition is causing unease among pharmaceutical companies and is being closely monitored by analysts.
Q: How could tariffs affect the financial performance of pharmaceutical companies?
A: According to Jefferies analyst Akash Tewari, a 25% tariff could possibly reduce sector profits by approximately 15%. Though, Tewari suggests that companies might mitigate the damage through actions such as stockpiling drugs, increasing drug prices, or shifting production to the United States. These efforts could potentially reduce the impact to a single-digit percentage.
Q: Are there any companies that are already feeling the effects of current tariffs?
A: Yes, some companies are already experiencing the impact of existing tariffs. For example, AbbVie anticipates a $30 million impact primarily related to its aesthetics business, as reported by Bloomberg. Merck estimates current tariffs, including a 10% levy on worldwide imports, will cost the company $200 million this year, according to The Guardian. these figures do not include the potential effect of more significant tariffs specifically targeting pharmaceutical imports.
Q: What steps are pharmaceutical companies considering in response to potential tariffs?
A: Some companies are exploring various strategies:
- Shifting Investments: Some are considering moving investments overseas.
- Wait-and-See Approach: Others are choosing to wait and assess the situation.
- Mitigation Strategies: Jefferies analyst Akash Tewari proposes mitigation methods like stockpiling drugs, raising prices, or moving production within the US.
Q: How could tariffs impact drug costs in the United states?
A: A report by Ernst & Young, cited by Reuters, indicates that a 25% tariff on pharmaceutical imports could potentially increase U.S. drug costs by nearly $51 billion annually. This could translate to price increases of up to 12.9% for consumers.
Q: Which countries are the major exporters of pharmaceuticals to the U.S.?
A: In 2023, the U.S. imported $203 billion worth of pharmaceutical products. A significant 73% of these imports originated from Europe, especially Ireland, Germany, and Switzerland.
Q: How are analysts advising investors considering these tariff threats?
A: Most analysts are advising investors to favor companies that have less exposure to the potential negative impacts of trade policies and other challenges the industry faces. They suggest focusing on companies with:
- rapid revenue growth
- Strong sales and profit prospects (through the 2030s)
- less exposure to tariffs
- Significant U.S.-based sales,production,and intellectual property
Q: Which pharmaceutical companies do analysts recommend as potential investments?
A: Cantor Fitzgerald analysts favor companies such as eli Lilly,AbbVie,Regeneron Pharmaceuticals,Gilead Sciences,Vertex Pharmaceuticals,and Vaxcyte due to their strong market positions and growth potential.
Q: What are the challenges facing the pharmaceutical sector aside from tariff threats?
A: The pharmaceutical sector faces multiple challenges:
- Slow growth
- missed forecasts
- Clinical trial setbacks
- Decline in company shares
Q: How are leading companies like Eli Lilly positioned in the market?
A: Cantor Fitzgerald analyst Carter Gould anticipates that Eli Lilly will solidify its position in the anti-obesity drug market, especially with its weight-loss pill Orforglipron and Mounjaro, compared to Novo Nordisk’s ozempic and Wegovy.
The details provided in this article is for informational purposes only and does not constitute financial advice. Always consult with a qualified financial advisor before making investment decisions.